67
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Mixed nanomicelles as potential carriers for systemic delivery of Z-GP-Dox, an FAPα-based doxorubicin prodrug: formulation and pharmacokinetic evaluation

, , , &
Pages 1625-1636 | Published online: 26 Feb 2015

References

  • ChristiansenVJJacksonKWLeeKNDownsTDMcKeePATargeting inhibition of fibroblast activation protein-alpha and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironmentsNeoplasia201315434835823555181
  • HuangSFangRXuJEvaluation of the tumor targeting of a FAPα-based doxorubicin prodrugJ Drug Target201119748749621284542
  • LiuXLLynnBCZhangJHA versatile prodrug approach for liposomal core-loading of water-insoluble camptothecin anticancer drugsJ Am Chem Soc2002124267650765112083906
  • GuptaSBiocompatible microemulsion systems for drug encapsulation and deliveryCurr Sci20111012174188
  • DuttaPDeyJDrug solubilization by amino acid based polymeric nanoparticles: characterization and biocompatibility studiesInt J Pharm2011421235336322001838
  • ZhangXZhangXYuPHanYLiYLiCHydrotropic polymeric mixed micelles based on functional hyperbranched polyglycerol copolymers as hepatoma-targeting drug delivery systemJ Pharm Sci2013102114515323132353
  • GillKKKaddoumiANazzalSMixed micelles of PEG(2000)-DSPE and vitamin-E TPGS for concurrent delivery of paclitaxel and parthenolide: enhanced chemosenstization and antitumor efficacy against non-small cell lung cancer (NSCLC) cell linesEur J Pharm Sci2012461–2647122369858
  • LiJHuoMRWangJRedox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxelBiomaterials20123372310232022166223
  • SaxenaVHussainMDFormulation and in vitro evaluation of 17-allyamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric mixed micelles for glioblastoma multiformeColloids Surf B Biointerfaces201311235035524012704
  • SaxenaVHussainMDPolymeric mixed micelles for delivery of curcumin to multidrug resistant ovarian cancerJ Biomed Nanotechnol2013971146115423909128
  • ChenYZhangWGuJEnhanced antitumor efficacy by methotrexate conjugated Pluronic mixed micelles against KBv multidrug resistant cancerInt J Pharm20134521–242143323688623
  • KataokaKHaradaANagasakiYBlock copolymer micelles for drug delivery: design, characterization and biological significanceAdv Drug Deliv Rev200147111313111251249
  • SongXJiangYRenCJNimodipine-loaded mixed micelles: formulation, compatibility, pharmacokinetics, and vascular irritability studyInt J Nanomedicine201273689369922888228
  • MehtaSKJindalNMixed micelles of lecithin-Tyloxapol as pharmaceutical nanocarriers for anti-tubercular drug deliveryColloids Surf B Biointerfaces2013110419442523751420
  • HammadMAMullerBWIncreasing drug solubility by means of bile salt-phosphatidylcholine-based mixed micellesEur J Pharm Biopharm19984633613679885310
  • RowlandMPeckCTuckerGPhysiologically-based pharmacokinetics in drug development and regulatory scienceAnnu Rev Pharmacol Toxicol201151457320854171
  • AtkinsonAJSmithBPModels of physiology and physiologically based models in clinical pharmacologyClin Pharmacol Ther20129213622713729
  • ChowECPangKSWhy we need proper PBPK models to examine intestine and liver oral drug absorptionCurr Drug Metab2013141577922935069
  • PangKSDurkMRPhysiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretionJ Pharmacokinet Pharmacodyn201037659161521153869
  • Rostami-HodjeganAPhysiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacologyClin Pharmacol Ther2012921506122644330
  • KaganLGershkovichPWasanKMMagerDEDual physiologically based pharmacokinetic model of liposomal and nonliposomal amphotericin B dispositionPharm Res2014311354523793994
  • RenTYCongLWangLipid emulsions in parenteral nutrition: current applications and future developmentsExpert Opin Drug Deliv201310111533154923919912
  • ZhangXZhangTZhouXEnhancement of oral bioavailability of tripterine through lipid nanospheres: preparation, characterization, and absorption evaluationJ Pharm Sci201410361711171924700417
  • ManoNMaoFHellerAA miniature biofuel cell operating in a physiological bufferJ Am Chem Soc200212444129621296312405819
  • LiuHSunHLuDIdentification of glucuronidation and biliary excretion as the main mechanisms for gossypol clearance: in vivo and in vitro evidenceXenobiotica201444869670724555821
  • LiuWLiuHSunHMetabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS)Xenobiotica201444545546424191862
  • KaganLGershkovichPWasanKMMagerDEPhysiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone®): pooled analysis of published dataAAPS J201113225526421431453
  • MayerLDTaiLCKoDSInfluence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in miceCancer Res19894921592259302790807
  • NieSUnderstanding and overcoming major barriers in cancer nano-medicineNanomedicine (Lond)20105452352820528447
  • ChoYWLeeJLeeSCHuhKMParkKHydrotropic agents for study of in vitro paclitaxel release from polymeric micellesJ Control Release200497224925715196752
  • AgrawalSKSanabria-DeLongNCoburnJMTewGNBhatiaSRNovel drug release profiles from micellar solutions of PLA-PEO-PLA triblock copolymersJ Control Release20061121647116507325
  • GuoSHuangLNanoparticles escaping RES and endosome: challenges for siRNA delivery for cancer therapyJ Nanomater2011201111221808638
  • HassanMHGhobaraMAbd-AllahGMModulator effects of meloxicam against doxorubicin-induced nephrotoxicity in miceJ Biochem Mol Toxicol201428833734624799355
  • MaedaHNakamuraHFangJThe EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivoAdv Drug Deliv Rev2013651717923088862